This study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of Sinotecean.

Inclusion Criteria:

• late malignant tumor patients diagnosed with the pathological and/or cytological;
• lack of the standard treatment or treatment failure;
• 18-65years, ECOG:0-1,expected survival period >3 months;
• main organs function is normal;
• signed and dated informed consent

Exclusion Criteria:

• participated in other clinical trials in four weeks;
• currently under other effective treatment;
• end of anti-tumor treatment within 4 weeks(end of Nitrosourea/Mitomycin within 6 weeks);
• AE ≥ Grade 2(according to NCI-CTC 4.0),except hair loss;
• with ischemic heart disease, heart failure, severe arrhythmia, cerebrovascular disease, asthma, severe infections, active peptic ulcer;
• urine protein: ++, and urinary in 24 hours > 1.0g;
• uncontrolled primary or metastatic brain;
• have immunodeficiency history;
• according to the researcher's judgment,there are concomitant diseases which will seriously endanger the patients or obstruct the patients to complete the clinical trial;